North America Vaccines Market to 2027 - Regional Analysis and Forecasts by Technology (Recombinant Vaccines, Conjugate Vaccines, Live Attenuated Vaccines, Inactivated and Subunit Vaccines, and Toxoid Vaccines); Disease Indication (DTP (Diphtheria Tetanus toxoids and Pertussis), Influenza, Hepatitis, Respiratory Syncytial Virus (RSV), and Other Diseases); Route of Administration (Oral, Injectable, and Other Routes of Administration); Patient Type (Pediatric Patients, and Adult Patients), and Country
Publication Month: Mar 2019
Report Code: TIPRE00003512 No. of Pages: 142 Category: Pharmaceuticals Status: Published
The North America human vaccines market is expected to reach US$ 24,510.0 Mn in 2027 from US$ 14,566.0 Mn in 2018. The market is estimated to grow with a CAGR of 6.0% from 2019-2027.
The growth of the market is driven by the factors such as compulsion or mandate vaccination and dropping vaccination rates. However, the market is likely to get impacted due to the low awareness about the benefits of vaccines during the forecast period.
The epidemic of measles in Disneyland in California, US has enforced the dropping of the rates for the vaccination. The instance took place in 2014, the epidemic of the measles has sickened approximately 111 people in California and has also spread to six other states as well as Canada and Mexico. The vaccination has been used safely and effectively for the decades and the rising numbers of the measles has led to more vaccinations. The children are more susceptible to falling prey to the diseases, therefore majority of the parents in US vaccinate their children on schedule.
Additionally, the vaccinations rates are reimbursed by the Medicaid and the reimbursement for Medicaid vaccine administration varies by state however it is as low as US$2 in some states. Also the use of the combination vaccines has been permitted by the Advisory Committee on Immunization Practices (ACIP) at the Centers for Disease Control (CDC). This is a safe and efficacious measure to decrease the number of injections needed to complete the childhood immunization schedule. Hence, the dropping rates of the vaccination rates are likely to raise the market significantly in the forecast period.
US is expected to lead the market in the North American region due to the rapid growth of the biopharmaceutical industry. The industry is experiencing the rapid growth due to technological advancements and increasing flexibility and low operational cost are also adding to the growth of the market. In addition, in the country the government has mandate the immunization and vaccination for preventable diseases. The growth of the market is also defined by the rising prevalence of the infectious and parasitic diseases as the diseases are alarming the need of the vaccination in the country. Therefore, considering the above mentioned factors the growth of the market in the country is likely to contribute largest share in the North American region during the forecast period.
Exhibit: Rest of North America Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
NORTH AMERICA VACCINES- MARKET SEGMENTATION
By Technology
- Recombinant vaccines
- Conjugate Vaccines
- Live Attenuated Vaccines
- Inactivated Vaccines
- Toxoid Vaccines
NORTH AMERICA VACCINES - MARKET SEGMENTATION
By Disease Indication
- DTP (diphtheria, tetanus, and pertussis)
- Influenza
- Hepatitis
- Other Diseases
NORTH AMERICA VACCINES - MARKET SEGMENTATION
By Rout of Administration
- Oral
- Injectable
- Other
NORTH AMERICA VACCINES - MARKET SEGMENTATION
By Patient Type
- Adults
- Pediatric
By Country
- U.S
- Canada
- Mexico
Companies Mentioned
- PFIZER INC
- GlaxoSmithKline plc.
- Merck & Co., Inc.
- Sanofi
- Johnson & Johnson Services, Inc
- Panacea Biotec Limited
- Astellas Pharma Inc.
- NOVAVAX, INC.
- VBI Vaccines Inc
- Bavarian Nordic.
PART 1. iNTRODUCTION
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
PART 2. North America Vaccines Market - Key takeaways
PART 3. North America Vaccines market - market landscape
3.1 overview
3.2 market segmentation
3.2.1 North America Vaccines Market - By Technology
3.2.2 North America Market - By Disease Indication
3.2.3 North America Vaccines Market - By Route of Administration
3.2.4 North America Vaccines Market - By Patient Type
3.2.5 North America Vaccines Market - By Country
3.3 PEST Analysis
PART 4. North America VAccines market- Key Market Dynamics
4.1 Key Market Drivers
4.1.1 Compulsion or Mandate Vaccination
4.1.2 Dropping Vaccination Rates
4.2 Key Market Restraints
4.2.1 Low Awareness About the Benefits of Vaccines
4.3 Key Market Opportunities
4.3.1 Rising Numbers of Diseases
4.4 future Trends
4.4.1 Advances in Vaccine Technology
4.5 Impact analysis
PART 5. VAccines market - North America Analysis
5.1 North America Vaccines market Revenue Forecasts and Analysis
5.2 Market positioning
5.3 PERFORMANCE OF KEY PLAYERS
PART 6. North America vaccines market Analysis - By TEchnology
6.1 Overview
6.2 NORTH AMERICA vaccines MARKET, BY Type, 2018 & 2027 (%)
6.3 North America Vaccines market Revenue And Forecasts to 2027, By echnology (US$ Mn)
6.4 Norh America Recombinant Vaccines Market
6.4.1 Overview
6.4.2 North America Recombinant Vaccines Market Revenue and Forecast to 2027 (US$ Mn)
6.5 North America Conjugate Vaccines Market
6.5.1 Overview
6.5.2 North America Conjugate Vaccines Market Revenue and Forecast to 2027 (US$ Mn)
6.6 North America Live Attenuated Vaccines Market
6.6.1 Overview
6.6.2 North America Live Attenuated Vaccines Market Revenue and Forecast to 2027 (US$ Mn)
6.7 North America Inactivated Vaccines Market
6.7.1 Overview
6.7.2 North America Inactivated Vaccines Market Revenue and Forecast to 2027 (US$ Mn)
6.8 North America toxoid Vaccines Market
6.8.1 Overview
6.8.2 North America Toxoid Vaccines Market Revenue and Forecast to 2027 (US$ Mn)
PART 7. North America Vaccines market Analysis - By Disease Indication
7.1 Overview
7.2 NORTH AMERICA vaccines MARKET, BY disease indication, 2018 & 2027 (%)
7.3 North America Vaccines market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
7.4 North America DTP (diphtheria, tetanus, and pertussis) Market
7.4.1 Overview
7.4.2 North America DTP (Diphtheria, Tetanus, And Pertussis) Market Revenue and Forecast to 2027 (US$ Mn)
7.5 North AMerica Influenza Market
7.5.1 Overview
7.5.2 North America Influenza Market Revenue and Forecast to 2027 (US$ Mn)
7.6 North America Hepatitis Market
7.6.1 Overview
7.6.2 North America Hepatitis Market Revenue and Forecast to 2027 (US$ Mn)
7.7 North America Other Diseases Market
7.7.1 Overview
7.7.2 North America Other Diseases Market Revenue and Forecast to 2027 (US$ Mn)
PART 8. North America Vaccines market Analysis - By Route of administration
8.1 Overview
8.2 NORTH AMERICA Vaccines MARKET, BY route of administration, 2018 & 2027 (%)
8.3 North America Vaccines market Revenue And Forecasts to 2027, By route of administration (US$ Mn)
8.4 North America Oral Market
8.4.1 Overview
8.4.2 North America Oral Market Revenue and Forecast to 2027 (US$ Mn)
8.5 North AMerica Injectable Market
8.5.1 Overview
8.5.2 North America Injectable Market Revenue and Forecast to 2027 (US$ Mn)
8.6 North America Other Routes of Administration Market
8.6.1 Overview
8.6.2 North America Other Routes of Administration Market Revenue and Forecast to 2027 (US$ Mn)
PART 9. North America Vaccines market Analysis - By Patient type
9.1 Overview
9.2 NORTH AMERICA Vaccines MARKET, BY patient type, 2018 & 2027 (%)
9.3 North America Vaccines market Revenue And Forecasts to 2027, By patient type (US$ Mn)
9.4 North America pediatric Market
9.4.1 Overview
9.4.2 North America Pediatric Market Revenue and Forecast to 2027 (US$ Mn)
9.5 North America adults Market
9.5.1 Overview
9.5.2 North America Adults Market Revenue and Forecast to 2027 (US$ Mn)
PART 10. North America Vaccines market Revenue and Forecasts to 2027
10.1 Overview
10.1.1 North America Vaccines Market Revenue And Forecasts to 2027 (US$ Mn)
10.1.2 North America Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
10.1.3 North America Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
10.1.4 North America Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
10.1.5 North America Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
10.1.6 North America Vaccines Market Revenue And Forecasts to 2027, By Country (%)
10.1.7 US Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.8 US Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.8.1 US Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
10.1.8.2 US Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
10.1.8.3 US Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
10.1.8.4 US Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
10.1.9 Canada Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.10 Canada Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.10.1 Canada Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
10.1.10.2 Canada Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
10.1.10.3 Canada Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
10.1.10.4.. Canada Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
10.1.11 Mexico Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.12 Mexico Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.12.1 Mexico Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
10.1.12.2 Mexico Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
10.1.12.3 Mexico Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
10.1.12.4 Mexico Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
PART 11. Vaccines Market -Industry Landscape
11.1 Overview
11.2 Comparative Company Analysis
11.3 Growth Strategies done by the companies in the Market, (%)
11.4 Organic Developments
11.4.1 Overview
11.5 Inorganic developments
11.5.1 Overview
PART 12. Vaccines Market-Key company profiles
12.1 PFIZER INC.
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Financial Overview
12.1.4 Product Portfolio
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 GlaxoSmithKline plc.
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Financial Overview
12.2.4 Product Portfolio
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Merck & Co., Inc.
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Financial Overview
12.3.4 Product Portfolio
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Sanofi
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Financial Information
12.4.4 Product Portfolio
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Johnson & Johnson Services, Inc.
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Financial Overview
12.5.4 Product Portfolio
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Panacea Biotec Limited
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Financial Information
12.6.4 Product Portfolio
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Astellas Pharma Inc.
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Financial Overview
12.7.4 Product Portfolio
12.7.5 Swot Analysis
12.7.6 Key Developments
12.8 NOVAVAX, INC.
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Financial Information
12.8.4 Product Pipeline
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 VBI Vaccines Inc.
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Financial Information
12.9.4 Product Portfolio
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 BAVARIAN NORDIC
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Financial Information
12.10.4 Product Pipeline
12.10.5 SWOT Analysis
12.10.6 Key Developments
PART 13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms
13.3 Methodology
13.3.1 Coverage
13.3.2 Secondary Research
13.3.3 Primary Research
LIST OF TABLES
TABLE 1. North America Vaccines market Revenue And Forecasts to 2027, By Technology (US$ Mn)
TABLE 2. North America Vaccines market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
TABLE 3. North America vaccines market Revenue And Forecasts to 2027, By route of administration (US$ Mn)
TABLE 4. North America vaccines market Revenue And Forecasts to 2027, By patient type (US$ Mn)
TABLE 5. North America Vaccines market Revenue And Forecasts to 2027, By Technology (US$ Mn)
TABLE 6. North America Vaccines market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
TABLE 7. North America Vaccines market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
TABLE 8. North America Vaccines market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
TABLE 9. US Vaccines market Revenue And Forecasts to 2027, By Technology (US$ Mn)
TABLE 10. US Vaccines market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
TABLE 11. US Vaccines market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
TABLE 12. US Vaccines market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
TABLE 13. CANADA Vaccines market Revenue And Forecasts to 2027, By Technology (US$ Mn)
TABLE 14. CANADA Vaccines market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
TABLE 15. CANADA Vaccines market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
TABLE 16. CANADA Vaccines market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
TABLE 17. MEXICO Vaccines market Revenue And Forecasts to 2027, By Technology (US$ Mn)
TABLE 18. MEXICO Vaccines market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
TABLE 19. MEXICO Vaccines market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
TABLE 20. MEXICO Vaccines market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
TABLE 21. Organic Developments Done By Companies
TABLE 22. Inorganic developments done by Companies
TABLE 23. Glossary of Terms, Vaccines market
LIST OF TABLES
FIGURE 1. US Vaccines market, Revenue (US$ Mn), By COuntry 2018 & 2027
FIGURE 2. north America Vaccines Market By Type, Market Share (%), 2018
FIGURE 3. north America vaccines Market By Disease indication, Market Share (%), 2018
FIGURE 4. North America Vaccines Market By route of Administration, Market Share (%), 2018
FIGURE 5. North America Vaccines Market By Patient Type, Market Share (%), 2018
FIGURE 6. Vaccines market Segmentation
FIGURE 7. North America PEST Analysis
FIGURE 8. Vaccines market impact analysis of drivers & Restraints
FIGURE 9. North America Vaccines market - Revenue Forecasts and Analysis - 2018- 2027
FIGURE 10. North America vaccines market, By Technology, 2018 & 2027 (%)
FIGURE 11. North America recombinant vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
FIGURE 12. North America conjugate vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
FIGURE 13. North America live attenuated vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
FIGURE 14. North America inactivated vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
FIGURE 15. North America toxoid vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
FIGURE 16. North America vaccines market By disease indication, 2017 & 2025 (%)
FIGURE 17. North America DTP (diphtheria, tetanus, and pertussis) Market Revenue and Forecasts to 2027 (US$ Mn)
FIGURE 18. North America influenza Market Revenue and Forecasts to 2027 (US$ Mn)
FIGURE 19. North America hepatitis Market Revenue and Forecasts to 2027 (US$ Mn)
FIGURE 20. North America Other Diseases Market Revenue and Forecasts to 2027 (US$ Mn)
FIGURE 21. North America vaccines market By route of administration, 2018 & 2027 (%)
FIGURE 22. North America oral Market Revenue and Forecasts to 2027 (US$ Mn)
FIGURE 23. North America injectable Market Revenue and Forecasts to 2027 (US$ Mn)
FIGURE 24. North America other routes of administration Market Revenue and Forecasts to 2027 (US$ Mn)
FIGURE 25. North America vaccines market By patient type, 2018 & 2027 (%)
FIGURE 26. North America pediatric Market Revenue and Forecasts to 2027 (US$ Mn)
FIGURE 27. North America adults Market Revenue and Forecasts to 2027 (US$ Mn)
FIGURE 28. North America Vaccines market revenue Overview, by Country (2017) (us $ mn)
FIGURE 29. North America Market Revenue and Forecasts to 2027 (US$ Mn)
FIGURE 30. North America Vaccines market Revenue And Forecasts to 2027, By Country (%)
FIGURE 31. US Vaccines market Revenue and Forecasts to 2027 (US$ Mn)
FIGURE 32. Canada Vaccines market Revenue and Forecasts to 2027 (US$ Mn)
FIGURE 33. Mexico Vaccines market Revenue and Forecasts to 2027 (US$ Mn)
FIGURE 34. Comparative Company Analysis
FIGURE 35. Growth Strategies done by the companies in the Market, (%)
The List of Companies
- PFIZER INC
- GlaxoSmithKline plc.
- Merck & Co., Inc.
- Sanofi
- Johnson & Johnson Services, Inc
- Panacea Biotec Limited
- Astellas Pharma Inc.
- NOVAVAX, INC.
- VBI Vaccines Inc
- Bavarian Nordic.
• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America Vaccines Market.
• Highlights key business priorities in order to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in the global North America Vaccines Market, thereby allowing players across the value chain to develop effective long-term strategies.
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
• Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution